# Neuralink — Healthcare Investment Intelligence

> medical_device · Series B. MedFuel Intel profile as of 2026-06-12.

Neuralink is an American neurotechnology company developing implantable brain-computer interfaces (BCIs) for treating serious brain diseases and human enhancement. As of 2024, it has conducted human implants, received FDA approval in May 2023, and is running clinical trials including for voice restoration[1][2][4].

## Key facts (as of 2026-06-12)
- Sector: medical_device
- Stage: Series B
- Website: https://neuralink.com

## MedFuel assessment
- Intelligence score: 0/100
- Analyses: 0
- Sentiment trend: stable

---
Source: MedFuel Intel — https://medfuelintel.com/company/neuralink-6. Figures reflect MedFuel's analysis; verify against primary sources (SEC, FDA, ClinicalTrials.gov) before any investment decision.